What Is Kisspeptin-10?
Kisspeptin-10 is a ten-amino-acid peptide and the shortest naturally occurring kisspeptin fragment that retains strong activity at the kisspeptin receptor. That receptor is now called KISS1R and was formerly known as GPR54.
The kisspeptin system acts near the top of the reproductive hormone pathway. Kisspeptin stimulates hypothalamic neurons that release gonadotrophin-releasing hormone, or GnRH. GnRH then signals the pituitary gland to release luteinising hormone, or LH, and follicle-stimulating hormone, or FSH. Those hormones regulate ovarian and testicular function.
Human experiments show that kisspeptin-10 can acutely increase LH in appropriate physiological settings. This makes it valuable as a research probe of the hypothalamic-pituitary-gonadal axis. It does not make kisspeptin-10 an approved fertility treatment, a general testosterone booster or a self-directed alternative to medical assessment.
Kisspeptin-10 must also be separated from kisspeptin-54. Both activate KISS1R, but they have different lengths and pharmacokinetic behaviour. Important IVF and hypothalamic-amenorrhoea studies have used kisspeptin-54. Those findings support the therapeutic potential of the pathway, not automatic equivalence between the two peptides.
What kind of molecule is kisspeptin-10?
Kisspeptin-10 is the decapeptide corresponding to the final ten amino acids of the larger human kisspeptin precursor. Its sequence is commonly written Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2. The amidated C-terminus is important for receptor activity.
The human KISS1 gene encodes a 145-amino-acid precursor. Processing can produce several biologically active peptides, commonly described as kisspeptin-54, kisspeptin-14, kisspeptin-13 and kisspeptin-10. They share the same active C-terminal region and can activate KISS1R.
Kisspeptin-54 was initially called metastin because KISS1 was discovered in research on suppression of tumour metastasis. The later discovery that KISS1R signalling is essential for puberty transformed the field. “Kisspeptin” now usually refers to the peptide family rather than one exact molecular length.
That naming can create confusion. A paper titled “kisspeptin administration” may have used KP-54, KP-10 or an analogue. The exact peptide, route, exposure and population must be checked before interpreting the result.
Why is it called kisspeptin?
The name reflects the location of the laboratory that identified KISS1 in Hershey, Pennsylvania, home of Hershey’s Kisses. The gene was originally studied because introducing it into certain cancer cells reduced metastatic behaviour without preventing formation of the primary tumour.
Researchers later identified peptide products of KISS1 as ligands for the orphan receptor GPR54. In 2003, human genetic studies showed that loss-of-function variants in GPR54 could cause hypogonadotropic hypogonadism and failure of normal pubertal development. This established the receptor as a central regulator of reproduction.
The receptor was subsequently renamed KISS1R. The older terms GPR54 and AXOR12 still appear in early papers and database searches. Metastin usually refers to kisspeptin-54, while the shorter active fragment is kisspeptin-10.
| Term | Meaning |
|---|---|
| KISS1 | Human gene encoding the kisspeptin precursor |
| KISS1R | Kisspeptin receptor, formerly GPR54 |
| Kisspeptin-54 | 54-amino-acid peptide also called metastin |
| Kisspeptin-10 | Ten-amino-acid C-terminal active fragment, also called KP-10 |
| GnRH | Hypothalamic hormone released downstream of kisspeptin signalling |
How does kisspeptin-10 work?
Kisspeptin-10 binds KISS1R, a G-protein-coupled receptor. Receptor activation commonly engages Gq/11 signalling, phospholipase C, inositol trisphosphate, diacylglycerol and intracellular calcium. In GnRH neurons, this supports depolarisation and GnRH release.
GnRH travels through the pituitary portal circulation to gonadotroph cells in the anterior pituitary. Pulsatile GnRH prompts LH and FSH secretion. LH and FSH then act on the gonads, influencing sex-steroid synthesis, follicular development, ovulation and sperm production.
This pathway is a hierarchy rather than a direct line from kisspeptin to testosterone or oestrogen. The response depends on whether GnRH neurons can respond, whether the pituitary can release gonadotrophins and whether the ovaries or testes can respond to LH and FSH.
A rise in LH after KP-10 therefore demonstrates preserved function across part of the axis. It does not guarantee a useful rise in sex steroids, ovulation, spermatogenesis, pregnancy or live birth.
Why do pulsatility and feedback matter?
The reproductive axis carries information through timing as well as concentration. GnRH is normally released in pulses. The frequency and amplitude of those pulses influence the balance of LH and FSH synthesis and release from the pituitary.
KNDy neurons are thought to help organise this rhythm. Neurokinin B provides stimulatory coordination within the network, while dynorphin contributes inhibitory control. Kisspeptin then supplies a major output to GnRH neurons. This model is supported by animal work, human genetics and pharmacological studies, although details in humans remain under investigation.
Sex-steroid feedback changes the system’s state. Most of the time, oestradiol and testosterone metabolites contribute negative feedback. Near ovulation, sustained high oestradiol helps switch the female reproductive axis towards positive feedback and an LH surge. The same KP-10 exposure can therefore meet a very different network in the early follicular and preovulatory phases.
This dynamic biology is why isolated hormone values are easy to overinterpret. A single LH concentration cannot show pulse frequency, and a short induced rise cannot establish restoration of a normal reproductive rhythm.
Where are kisspeptin neurons found?
Important kisspeptin populations are located in the hypothalamus. Human anatomy differs in detail from commonly used rodent models, but kisspeptin neurons in the infundibular or arcuate region are involved in pulsatile GnRH control. A population in the rostral preoptic region is implicated in positive feedback and the preovulatory surge.
Many arcuate kisspeptin neurons co-express neurokinin B and dynorphin. They are often called KNDy neurons, using the initial letters of kisspeptin, neurokinin B and dynorphin. Interactions within this network help generate rhythmic output that coordinates GnRH pulses.
Sex steroids feed back onto the network. Oestradiol, progesterone and testosterone can alter kisspeptin expression and neuronal activity according to brain region and physiological state. This helps explain why an identical experimental dose can produce different endocrine responses across sexes and menstrual-cycle phases.
KISS1 and KISS1R are also expressed outside the hypothalamus, including placenta and other tissues. Detection outside the brain has prompted research into pregnancy, metabolism and cancer. Expression alone does not establish that administering KP-10 will produce a useful clinical effect in those tissues.
Why is kisspeptin essential for puberty?
Puberty requires activation of pulsatile GnRH secretion. Human loss-of-function mutations affecting KISS1R can prevent this activation, causing hypogonadotropic hypogonadism. Affected individuals have low sex-steroid production because hypothalamic signalling fails to drive normal pituitary gonadotrophin release.
Conversely, activating changes in the kisspeptin pathway have been associated with central precocious puberty. Together, these genetic observations provide unusually strong evidence that kisspeptin signalling is causal, not merely correlated with reproductive maturation.
Genetic disease does not mean that ordinary variations in puberty are caused by a simple lack of kisspeptin. Pubertal timing reflects genes, nutrition, energy balance, chronic disease and environmental influences. A peptide challenge cannot replace a complete endocrine evaluation.
The genetic findings also do not prove that external KP-10 is a suitable long-term treatment. A functioning receptor pathway, repeated pharmacological exposure and normal physiological pulsatility are separate questions.
What did early human studies in men show?
Controlled experiments in healthy men established that intravenous kisspeptin-10 can produce a rapid LH response. One study found that bolus administration potently evoked LH secretion and that continuous infusion increased testosterone, LH pulse frequency and pulse size during the observation period.
Another study used frequent blood sampling to examine the timing of pulses. A single KP-10 bolus triggered an immediate LH pulse regardless of when the previous endogenous pulse had occurred. The investigators inferred that kisspeptin could reset the hypothalamic GnRH pulse generator.
These studies were mechanistic and small. Their strength lies in dense hormone sampling and within-person control, not in demonstrating treatment outcomes. Participants were healthy men, and the observation windows were short.
The dose-response was not simply “more produces more”. In one experiment, the LH response to 3 micrograms per kilogram was lower than the response to 1 microgram per kilogram. This could reflect rapid receptor or network dynamics and warns against assuming a linear relationship.
What did studies in women show?
Responses in women vary across the menstrual cycle and with sex-steroid feedback. A KP-10 study found little or no gonadotrophin response during the follicular phase under the tested conditions, while responses were clearer in the preovulatory phase. This phase dependence is biologically important and helps explain apparently inconsistent findings.
Another study compared groups with different sex-steroid environments. The gonadotrophin response to KP-10 was enhanced in postmenopausal women with low sex-steroid feedback and suppressed in women taking exogenous oestrogen and progestogen. The experiment assessed an acute intravenous response, not fertility treatment.
Research across the cycle indicates that the reproductive axis is not equally receptive at all times. Baseline GnRH activity, pituitary readiness, oestrogen feedback and receptor sensitivity can change. A hormone result from one phase cannot be treated as the expected response in another.
Small participant numbers remain a limitation. Menstrual-cycle studies are demanding because phase must be confirmed and frequent blood sampling is needed. Repeated findings support the physiology, but they do not define an approved therapeutic protocol.
How do KP-10 and KP-54 differ in exposure?
KP-10 contains only the shared receptor-activating tail of the kisspeptin family. It is rapidly cleared from the circulation, which can make it useful for short, tightly timed physiological experiments. KP-54 is larger and generally produces longer exposure.
The two peptides can generate comparable gonadotrophin responses under some intravenous study conditions, but comparable acute receptor activation does not erase pharmacokinetic differences. Route and infusion pattern can further alter the concentration-time profile.
This matters when interpreting fertility research. A brief KP-10 pulse may be suitable for asking whether the GnRH network responds at a particular moment. A longer-acting peptide may be chosen when researchers want a more sustained signal. Neither profile is inherently superior for every purpose.
Analogues designed to resist enzymatic breakdown may extend activity further. Once the sequence is modified, however, it is a new molecule with its own selectivity, exposure, toxicology and evidence requirements. Results cannot be filed under ordinary KP-10 merely because the analogue targets KISS1R.
What is tachyphylaxis and why does it matter?
Tachyphylaxis is a rapid reduction in response during repeated or continuous exposure. Reproductive hormones normally operate in pulses, and continuous stimulation can alter receptor and network behaviour. GnRH itself illustrates the principle: pulsatile and continuous delivery can produce very different pituitary outcomes.
Repeated kisspeptin-54 administration in women with hypothalamic amenorrhoea produced an acute response but reduced responsiveness with more frequent exposure in an early study. A later twice-weekly schedule maintained hormonal effects for longer. These were KP-54 studies and should not be rewritten as KP-10 evidence.
Short KP-10 infusions in men did not always show rapid loss of response. Recent small studies have investigated longer continuous or intermittent KP-10 exposure, including a 2026 report in healthy men. Such work is informative but participant numbers remain too small to establish a general long-term treatment strategy.
Different findings may reflect peptide length, route, amount, sex, baseline reproductive state and exposure pattern. “Kisspeptin causes tachyphylaxis” and “kisspeptin never causes tachyphylaxis” are both too broad.
What is functional hypothalamic amenorrhoea?
Functional hypothalamic amenorrhoea, or FHA, is loss of menstrual cycles caused by suppression of hypothalamic reproductive signalling without an anatomical lesion. Low energy availability, weight change, intensive exercise and psychological stress can contribute. The condition involves reduced GnRH and LH pulsatility and low oestrogen exposure.
Kisspeptin is relevant because it sits upstream of GnRH. Studies have examined circulating patterns, hormone responses and whether external kisspeptin can temporarily restore pulsatile signalling.
Much of the intervention evidence in FHA uses kisspeptin-54. Continuous intravenous KP-54 increased LH pulsatility during short experiments, and intermittent schedules produced hormonal responses. These results show that the axis can retain responsiveness in some participants.
They do not prove that KP-10 treats the underlying drivers of FHA or restores long-term bone, cardiovascular and fertility outcomes. Nutritional, exercise, psychological and medical factors still require assessment. A temporary LH response is a biomarker, not recovery from the condition.
Could kisspeptin be used in fertility treatment?
The leading clinical idea is that controlled kisspeptin-receptor activation could trigger the reproductive axis more physiologically upstream than directly administering some downstream hormones. Researchers have explored follicular maturation, ovulation triggering and diagnostic testing.
The best-known IVF studies used kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome. Oocyte maturation and live births were reported, and the approach was investigated because excessive ovarian stimulation can be dangerous.
This is encouraging pathway evidence, but it is not a KP-10 trial result. KP-54 has a longer circulating half-life and a larger evidence base in these IVF experiments. A clinic cannot substitute KP-10 by counting amino acids or assuming receptor activation makes the products equivalent.
Fertility outcomes form a hierarchy. Hormone release comes before follicular response, mature oocytes, fertilisation, embryo development, pregnancy and live birth. A study showing increased LH answers an early mechanistic question, not the final clinical one.
Could KP-10 become a reproductive diagnostic test?
An upstream challenge could potentially help locate dysfunction within the reproductive axis. If KP-10 produces LH release, this suggests that kisspeptin-responsive GnRH neurons, pituitary gonadotrophs and the intervening signalling pathway retain function. A weak response could arise at several levels and would need comparison with GnRH testing and baseline clinical information.
Researchers have explored kisspeptin responses in people with oligo-amenorrhoea and other reproductive disorders. The concept is attractive because GnRH testing acts directly at the pituitary, while kisspeptin challenges the system one level higher.
A useful diagnostic test needs more than a group-average difference. It requires a standardised product, administration method, sampling schedule and reference range. Thresholds must separate relevant diagnoses with adequate sensitivity and specificity, and the result must change clinical decisions or outcomes.
Menstrual phase, sex-steroid exposure, age and existing endocrine treatment could all influence the response. Until those variables are handled in validated prospective studies, KP-10 is better described as a research probe than a clinical diagnostic.
What has been studied in hyperprolactinaemia and PCOS?
High prolactin can suppress reproductive function and cause amenorrhoea. A small study examined KP-10 in women with chronic amenorrhoea associated with hyperprolactinaemia and measured activation of the hypothalamic-pituitary-ovarian axis. Such work asks whether the downstream GnRH system remains recruitable despite prolactin-related suppression.
Polycystic ovary syndrome, or PCOS, can involve increased LH pulsatility and altered feedback. Researchers have studied kisspeptin and neurokinin B interactions in women with PCOS. A maintained LH response to KP-10 after neurokinin-3 receptor blockade provides mechanistic information about pathway order.
Neither condition should be reduced to “too little” or “too much” kisspeptin. Hyperprolactinaemia has multiple causes, including medicines and pituitary disease. PCOS is heterogeneous and involves reproductive, metabolic and androgen-related features. Hormonal challenge studies do not establish routine treatment.
Does kisspeptin-10 increase testosterone?
KP-10 can increase LH in healthy men, and LH stimulates testicular Leydig cells to produce testosterone. Some short studies therefore recorded a downstream testosterone rise. The size and timing of response depend on baseline state and exposure.
This is not evidence that KP-10 is an established treatment for low testosterone. Hypogonadism can result from hypothalamic, pituitary or testicular causes. If the testes cannot respond, increasing upstream signalling may not correct the problem. If the cause is reversible illness, energy deficit, a medicine or a pituitary lesion, a peptide could obscure rather than solve it.
Testosterone concentration is also a surrogate measure. A therapy must be judged by symptoms, fertility goals, adverse effects and long-term outcomes as well as laboratory change. Research amounts are not recommendations for personal use.
Does kisspeptin affect sexual or emotional processing?
Kisspeptin neurons connect reproductive state with wider brain networks, prompting research into sexual attraction, reward and emotion. Human imaging studies have reported changes in limbic brain activity after kisspeptin administration, with some associations involving sexual and couple-bonding stimuli.
These experiments generally used controlled intravenous administration and often used kisspeptin-54. Brain-imaging signals are not the same as improved libido, erectile function, relationship satisfaction or mental health.
The work is scientifically interesting because reproduction requires integration of hormones, motivation and environment. It should not be marketed as proof of an aphrodisiac. Larger clinical trials using patient-relevant outcomes would be needed.
Does kisspeptin regulate metabolism?
Reproductive function is sensitive to energy availability. Leptin, insulin, stress signals and nutritional state interact with hypothalamic networks that include kisspeptin neurons. Animal studies have investigated whether impaired kisspeptin signalling affects body weight, glucose regulation and energy expenditure.
This does not establish KP-10 as a metabolic or weight-loss peptide. Much of the evidence is preclinical, and deleting a signalling pathway throughout an animal’s development is not equivalent to administering a fragment to an adult human.
The strongest near-term implication is physiological: the reproductive axis integrates information about energy sufficiency. Metabolic disease and energy deficit can therefore alter reproductive hormone patterns. Claims of direct fat loss or glucose treatment remain unsupported.
What is known about cancer biology?
KISS1 was first identified as a metastasis-suppressor gene, and laboratory studies have examined KISS1 and KISS1R across multiple cancers. Associations vary by tumour type and experimental system. Expression can relate to migration, invasion, prognosis or hormone signalling, but the biology is not uniform.
The original gene-level finding should not be converted into a claim that injected KP-10 prevents or treats cancer. Gene expression, local production of peptide, receptor presence and systemic pharmacological administration are different interventions.
There is no established oncology indication for KP-10. People should be particularly cautious of commercial claims that borrow the term “metastasis suppressor” while omitting the absence of therapeutic trials.
How is kisspeptin-10 manufactured?
KP-10 can be produced by solid-phase peptide synthesis. The chain is assembled from protected amino acids while attached to a resin, generally from the C-terminus towards the N-terminus. The terminal amide must be incorporated correctly because it contributes to the native active structure.
After cleavage and deprotection, the crude product can contain deletion sequences, truncated chains, incompletely deprotected material, modified side chains and residual reagents. Reverse-phase chromatography is commonly used for purification. Mass spectrometry can help confirm molecular mass, while chromatographic methods assess related substances.
Identity and purity do not establish biological potency on their own. A robust specification can include peptide content, water, counterions, residual solvents, elemental impurities and a receptor-based or other suitable potency assay.
For sterile human research material, additional controls include bioburden, bacterial endotoxins, sterility, particulate matter, container integrity and stability. Published human studies may use material manufactured under good manufacturing practice. That is materially different from an online vial accompanied only by a generic certificate.
What affects kisspeptin-10 stability?
Shorter peptides can still degrade through oxidation, deamidation, hydrolysis or other chemical pathways. Adsorption to containers and tubing can reduce the amount available at low concentrations. Temperature, pH, buffer, oxygen, light and repeated handling may matter.
The tryptophan-containing sequence avoids methionine, a common oxidation target, but this does not make KP-10 immune to degradation. The amidated end and complete sequence must remain intact for the intended molecule to be present.
Stability is formulation specific. Data for one buffer, concentration and container cannot validate another. A freeze-dried appearance does not prove that a product was synthesised correctly or remained stable before arrival.
What do human studies tell us about safety?
Small acute studies in research settings have generally reported that KP-10 was tolerated during short observation. This is reassuring for those experiments but does not establish broad safety.
The main expected pharmacological concern is unwanted activation of the reproductive axis. Consequences could differ by sex, age, menstrual state, pregnancy potential, hormone-sensitive disease and concurrent treatment. Long-term effects on receptor responsiveness and reproductive physiology remain incompletely characterised.
Rare adverse effects cannot be estimated reliably from studies involving a handful or a few dozen participants. Pregnancy safety, developmental exposure, use in adolescents outside specialised research and interaction with fertility medicines require specific evidence.
Product quality is a separate safety question. Incorrect content, microbial contamination or endotoxin can cause harm unrelated to kisspeptin pharmacology. No favourable journal article can validate a product that was not used in that study.
Is kisspeptin-10 approved?
At this guide’s September 2026 review date, kisspeptin-10 was not an FDA-approved or UK-authorised medicine. It remains an investigational research peptide.
Kisspeptin-54 has also been investigated rather than generally approved as a fertility medicine. Trials and specialist research programmes do not create approval for commercial products sold under either name.
Approval would require a defined manufacturer, formulation, indication, evidence package, quality system and prescribing information. The pathway’s biological importance is not a substitute for that process.
What kinds of kisspeptin medicines are developers exploring?
Development strategies include native KP-10, KP-54, modified agonists with longer exposure and KISS1R antagonists. Agonists aim to stimulate the reproductive axis. Antagonists aim to suppress or study kisspeptin signalling.
A longer-acting agonist could reduce the need for continuous delivery, but prolonged stimulation might change receptor responsiveness or disrupt physiological timing. A short-acting molecule offers experimental control but can be inconvenient as a medicine. Drug design therefore involves a trade-off between duration, controllability and preservation of useful endocrine patterns.
Antagonists may help researchers test causal mechanisms and could have different future uses from agonists. Evidence for an antagonist cannot be used to support a commercial KP-10 product, even when both involve KISS1R.
This pipeline remains investigational. A patent, company programme or registered trial indicates development activity, not proven efficacy or regulatory approval.
How does kisspeptin-10 compare with GnRH and gonadorelin?
| Compound | Primary target | Position in the pathway | Evidence context |
|---|---|---|---|
| Kisspeptin-10 | KISS1R | Upstream stimulation of GnRH neurons | Small mechanistic human studies; investigational |
| Kisspeptin-54 | KISS1R | Upstream stimulation of GnRH neurons | Broader fertility research; investigational |
| GnRH or gonadorelin | GnRH receptor at the pituitary | Direct stimulation of pituitary LH and FSH release | Established diagnostic and historical therapeutic uses vary by product and country |
| GnRH agonist analogues | GnRH receptor | Initial stimulation followed by downregulation with sustained exposure | Approved medicines exist for defined indications |
A KP-10 response depends on functioning GnRH neurons and downstream pituitary capacity. A GnRH challenge acts one level lower and can help assess pituitary responsiveness. This conceptual difference could support future diagnostic use, but validated thresholds and clinical utility are still needed.
What remains unknown?
Researchers have not yet established an approved therapeutic role, optimal clinical formulation or long-term benefit-risk profile for KP-10. It remains unclear which disorders would benefit from upstream stimulation rather than existing hormonal treatments.
More evidence is needed on repeated exposure, tachyphylaxis, sex-specific response, pregnancy, adolescents, hormone-sensitive conditions and diverse populations. Comparative studies must also determine when KP-10, KP-54 or a longer-acting analogue is most suitable.
Clinical outcomes matter. Future studies should move beyond LH and FSH to ovulation, sperm production, pregnancy, live birth, symptoms, bone health and adverse outcomes where relevant. A sophisticated mechanism does not guarantee a useful medicine.
Frequently asked questions
Is kisspeptin-10 a peptide?
Yes. It is an amidated peptide containing ten amino acids.
Is kisspeptin-10 naturally present in humans?
Yes. It is one of the active peptide fragments derived from the human KISS1 precursor.
Is KP-10 the same as kisspeptin-54?
No. They share the active C-terminal sequence and receptor target, but they differ in length, exposure and clinical evidence.
What receptor does KP-10 activate?
It activates KISS1R, formerly called GPR54.
Does KP-10 release GnRH?
Human hormone studies support stimulation of GnRH-dependent LH release. Direct measurement of GnRH in humans is difficult, so frequent LH sampling is often used as a downstream readout.
Does kisspeptin-10 increase LH?
It can produce a strong acute LH response, particularly in healthy men and in women under receptive hormonal conditions.
Does it increase FSH as strongly as LH?
FSH responses are generally smaller or less consistent than LH responses in acute studies because secretion and clearance are regulated differently.
Does kisspeptin-10 increase testosterone?
Some short studies in healthy men recorded downstream testosterone increases after LH stimulation. This does not establish treatment for hypogonadism.
Can it trigger ovulation?
The kisspeptin pathway can stimulate the reproductive axis, and KP-54 has been used to trigger oocyte maturation in IVF research. That evidence should not be assigned directly to KP-10.
Is kisspeptin-10 a fertility medicine?
No approved general fertility indication has been established. It remains investigational.
Does KP-10 treat hypothalamic amenorrhoea?
The pathway is scientifically relevant, but much of the interventional FHA evidence uses KP-54. Hormone responses do not establish long-term recovery or treatment of underlying causes.
Is kisspeptin-10 an aphrodisiac?
No. Research on sexual and emotional brain processing does not establish a reliable libido or sexual-performance treatment.
Does it cause tachyphylaxis?
Responsiveness can depend on the peptide, pattern of exposure and population. KP-54 studies have shown reduced response with some repeated schedules, while limited KP-10 studies have produced different findings.
Is kisspeptin-10 approved by the FDA?
No, not as of September 2026.
Are online KP-10 products equivalent to clinical material?
No. A product name or purity claim does not establish identity, peptide content, potency, sterility, endotoxin control or stability.
Are experimental amounts recommendations?
No. They document study design and should not be used as self-administration instructions.
Sources
Research reviewed through September 2026.